1 unknown. 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Unknown 1 |
Follow Atrial Fibrillation Recurrent: new trials by email Literature Review of Atrial Fibrillation Recurrent trials Research Report on Atrial Fibrillation Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation. Dapagliflozin, Placebo - Atrial Fibrillation Recurrent, Pulmonary Venous Isolation | Early Phase 1 | Unknown | G.Gennimatas General Hospital | 350 | 2021-09-01 | 2021-07-27 |
Atrial Fibrillation (1) · Recurrence (1)
Arrhythmias, Cardiac (1) · Cardiovascular Diseases (1) · Disease Attributes (1) · Heart Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
dapagliflozin (1)
G.Gennimatas General Hospital (1)
Greece (1)
PMID 23537812, PMID 26378978, PMID 28605608, PMID 29311992, PMID 30093883, PMID 30132036, PMID 30415602, PMID 30874766, PMID 31431051, PMID 31535829, PMID 31970162, PMID 32613148, PMID 32847602, PMID 32865377, PMID 32877652, PMID 32970396, PMID 9725923